The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - Janssen (Inst); Takeda (Inst)
Subcutaneous daratumumab (DARA SC) versus active monitoring in patients (pts) with high-risk smoldering multiple myeloma (SMM): Randomized, open-label, phase 3 AQUILA study.
 
Meletios A. Dimopoulos
Honoraria - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda
Consulting or Advisory Role - Amgen; Beigene; Bristol-Myers Squibb; Janssen-Cilag; Takeda
 
Peter M. Voorhees
Consulting or Advisory Role - Abbvie/Genentech; Bristol-Myers Squibb; GlaxoSmithKline; Janssen; Karyopharm Therapeutics; Oncopeptides; Pfizer; Sanofi; Secura Bio
Research Funding - Abbvie (Inst); GlaxoSmithKline (Inst); Janssen (Inst); TeneoBio (Inst)
Travel, Accommodations, Expenses - Sanofi
(OPTIONAL) Uncompensated Relationships - GlaxoSmithKline
 
Hartmut Goldschmidt
Honoraria - Amgen; Bristol-Myers Squibb; Celgene; Chugai Pharma; GlaxoSmithKline; Janssen-Cilag; Novartis; Sanofi
Consulting or Advisory Role - Adaptive Biotechnologies (Inst); Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Janssen-Cilag (Inst); Sanofi (Inst); Takeda (Inst)
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Chugai Pharma Europe (Inst); Incyte (Inst); Janssen (Inst); Molecular Partners (Inst); MSD (Inst); Mundipharma (Inst); Novartis (Inst); Sanofi (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Janssen-Cilag; Sanofi
Other Relationship - Amgen (Inst); Celgene/Bristol-Myers Squibb (Inst); Chugai Pharma Europe (Inst); Janssen (Inst); Sanofi (Inst)
 
Ross I. Baker
Consulting or Advisory Role - Janssen-Cilag (Inst); Roche (Inst)
Speakers' Bureau - Bayer (Inst); Bristol-Myers Squibb (Inst); Cardinal Health (Inst)
Research Funding - Abbvie (Inst); Acerta Pharma (Inst); Alexion Pharmaceuticals (Inst); Amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); CSL Behring (Inst); Daiichi Sankyo (Inst); Janssen-Cilag (Inst); MorphoSys (Inst); Pfizer (Inst); Portola Pharmaceuticals (Inst); Rigel (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst); Technoclone (Inst)
 
Yingqi Shi
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson; Merck; Pfizer
 
Els Rousseau
Employment - Janssen
 
Robyn Monet Dennis
Employment - Janssen
Stock and Other Ownership Interests - Novavax
 
Robin L. Carson
Employment - Janssen
 
S. Vincent Rajkumar
No Relationships to Disclose